Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell–derived hematopoiesis model
Authors:
- Annelise Bennaceur-GriscelliABAnnelise Bennaceur-Griscelli
- Yannick ValogneYVYannick Valogne
- Stephane FlamantSFStephane Flamant
- Jean-Claude ChomelJCJean-Claude Chomel
- Nathalie SorelNSNathalie Sorel
- Marie-Laure BonnetMBMarie-Laure Bonnet
- Michael W. DeiningerMDMichael W. Deininger
- Maria-Teresa Mitjavila-GarciaMMMaria-Teresa Mitjavila-Garcia
- Ali G. TurhanATAli G. Turhan
- 1 April 2013
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 41 (4) , 335-345.e3
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance ProfileCancer Research, 2011
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Cancer Cell, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJournal of Clinical Investigation, 2011
- Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemiaNature Medicine, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Lin28 promotes transformation and is associated with advanced human malignanciesNature Genetics, 2009
- Cancer induction by restriction of oncogene expression to the stem cell compartmentThe EMBO Journal, 2008
- Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProceedings of the National Academy of Sciences, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004